DK1032560T3 - I 4-position substituerede 2-pyrrolidinon-derivater til reduktion af det ekstracellulære - Google Patents

I 4-position substituerede 2-pyrrolidinon-derivater til reduktion af det ekstracellulære

Info

Publication number
DK1032560T3
DK1032560T3 DK98963476T DK98963476T DK1032560T3 DK 1032560 T3 DK1032560 T3 DK 1032560T3 DK 98963476 T DK98963476 T DK 98963476T DK 98963476 T DK98963476 T DK 98963476T DK 1032560 T3 DK1032560 T3 DK 1032560T3
Authority
DK
Denmark
Prior art keywords
alkyl
alkylamino
alkoxy
pyrrolidinone derivatives
extracellular
Prior art date
Application number
DK98963476T
Other languages
English (en)
Inventor
Thomas J Feuerstein
Rainer Knoerle
Original Assignee
Univ Ludwigs Albert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ludwigs Albert filed Critical Univ Ludwigs Albert
Application granted granted Critical
Publication of DK1032560T3 publication Critical patent/DK1032560T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
DK98963476T 1997-11-18 1998-11-17 I 4-position substituerede 2-pyrrolidinon-derivater til reduktion af det ekstracellulære DK1032560T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19751062A DE19751062A1 (de) 1997-11-18 1997-11-18 An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
PCT/EP1998/007383 WO1999025683A1 (de) 1997-11-18 1998-11-17 An 4-stellung substituierte 2-pyrrolidinon-derivate zur verringerung des extrazellulären glutamat-spiegels
EP98963476A EP1032560B1 (de) 1997-11-18 1998-11-17 An 4-stellung substituierte 2-pyrrolidinon-derivate zur verringerung des extrazellulären glutamat-spiegels

Publications (1)

Publication Number Publication Date
DK1032560T3 true DK1032560T3 (da) 2005-04-04

Family

ID=7849081

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98963476T DK1032560T3 (da) 1997-11-18 1998-11-17 I 4-position substituerede 2-pyrrolidinon-derivater til reduktion af det ekstracellulære

Country Status (11)

Country Link
US (1) US6384069B1 (da)
EP (2) EP1032560B1 (da)
JP (1) JP2001523659A (da)
AT (1) ATE285768T1 (da)
CA (1) CA2310319A1 (da)
CY (1) CY1105658T1 (da)
DE (2) DE19751062A1 (da)
DK (1) DK1032560T3 (da)
ES (1) ES2232976T3 (da)
PT (1) PT1032560E (da)
WO (1) WO1999025683A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6781030B1 (en) 1998-11-02 2004-08-24 Trustee Of Tufts College, Ballou Hall Methods for cloning mammals using telophase oocytes
FR2796552A1 (fr) * 1999-07-21 2001-01-26 Centre Nat Rech Scient Nouvelle utilisation de derives de la beta-naphtoquinone et de leurs sels pour la fabrication de medicaments exercant un effet inhibiteur sur la liberation de glutamate dans le cerveau
ES2169690B1 (es) * 2000-10-06 2004-03-16 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.
DE10210190A1 (de) * 2002-03-07 2003-09-25 Sanol Arznei Schwarz Gmbh Aza-Spiroverbindungen
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
EP1529528A1 (en) * 2003-11-07 2005-05-11 Universitätsklinikum Freiburg 2-pyrrolidone derivatives and their use in protecting mammalian cells against oxidation stress
WO2012028959A1 (en) 2010-08-31 2012-03-08 Pablo Villoslada Agonists of neurotrophin receptors and their use as medicaments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445664A1 (de) * 1963-07-04 1969-11-27 Klinke Desitin Werk Verfahren zur Herstellung von alpha,alpha-disubstituierten Succinimiden
DD130243A1 (de) * 1977-03-23 1978-03-15 Wolfgang Kuehne Verfahren zur herstellung von alpha,alpha-disubstituierten bernsteinsaeureimiden
DE3631414A1 (de) * 1986-09-16 1988-03-24 Basf Ag Verfahren zur herstellung von (alpha)-pyrrolidonen, deren verwendung und neue (alpha)-pyrrolidone
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5420154A (en) * 1990-08-03 1995-05-30 Smithkline Beecham Corp. TNF inhibitors
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
PT888325E (pt) * 1996-02-07 2002-10-31 Warner Lambert Co Novos amino acidos ciclicos como agentes farmaceuiticos
DK0888286T3 (da) 1996-03-14 2002-02-18 Warner Lambert Co Nye substituerede cykliske aminosyrer som farmaceutiske midler
NZ331142A (en) * 1996-03-14 2001-04-27 Warner Lambert Co Bridged cyclic amino acids as pharmaceutical agents

Also Published As

Publication number Publication date
EP1032560B1 (de) 2004-12-29
US6384069B1 (en) 2002-05-07
EP1032560A1 (de) 2000-09-06
ES2232976T3 (es) 2005-06-01
CA2310319A1 (en) 1999-05-27
PT1032560E (pt) 2005-04-29
DE59812460D1 (de) 2005-02-03
JP2001523659A (ja) 2001-11-27
EP1486487A1 (de) 2004-12-15
ATE285768T1 (de) 2005-01-15
CY1105658T1 (el) 2010-12-22
WO1999025683A1 (de) 1999-05-27
DE19751062A1 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
AP1526A (en) Sertraline salts and sustained-release dosage forms of sertraline.
DK0893998T4 (da) Afgivelse af nikotin i tyktarmen med henblik på behandling af inflammatoriske tarmsygdomme
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CA2392050C (en) Pharmaceutical formulations containing zolmitriptan
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
NZ519425A (en) Solutions containing epinastin
DK1032560T3 (da) I 4-position substituerede 2-pyrrolidinon-derivater til reduktion af det ekstracellulære
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
AU755402B2 (en) Method of treating impotence due to spinal cord injury
MY124465A (en) Reduction of infarct volume using citicoline
Wang et al. The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
TW200503732A (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives and methods of use thereof
Chiou et al. Studies on the involvement of melatonergic mechanism in intraocular pressure regulation
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
MX2023010971A (es) Formulacion de laquinimod para uso ocular.
CA2132102A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists
IE790157L (en) Therapeutic agents
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
AP2002002662A0 (en) Sertraline salts and sustained-release dosage forms of sertraline
WO2004050019A9 (en) Method and compositions for treating anxiety